Screener
Rigel Pharmaceuticals RIGL Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating activities | ||
| Net income | $8,654 | $11,446 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||
| Stock-based compensation expense | 3,456 | 3,324 |
| Depreciation and amortization | 597 | 604 |
| Deferred income tax | 2,573 | — |
| Net amortization of discount on short-term investments and term loans | (170) | (190) |
| Changes in assets and liabilities: |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's stock-based comp?
- Rigel Pharmaceuticals (RIGL) reported stock-based comp of $3.46M in Q1 2026.
- How has Rigel Pharmaceuticals's stock-based comp changed year-over-year?
- Rigel Pharmaceuticals's stock-based comp increased by 4.0% year-over-year, from $3.32M to $3.46M.
- What is the long-term trend for Rigel Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's stock-based comp has grown at a 7.6% compound annual growth rate (CAGR), from $9.49M to $12.71M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Rigel Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude